Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2a1]
Substrate: CDC2

Description: Cell division control protein 2 homolog (EC 2.7.11.22) (EC 2.7.11.23)(p34 protein kinase) (Cyclin-dependent kinase 1) (CDK1).

Ensembl ID: ENSG00000170312

UniprotKB/SwissProt: CDC2_HUMAN (P06493)

Function: Plays a key role in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S-phase and mitosis. p34 is a component of the kinase complex that phosphorylates the repetitive C-terminus of RNA polymerase II.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Nucleus (By similarity).
PDB:1LC9
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of CDC2

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89% Swiss-Prot 55.0 View   
2CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89%MYT1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
3CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89% Phospho.ELM 7.0View   
4CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89%Q01538(Myelin transcription factor 1) HPRD:00302(in vitro;in vivo) ViewAnalyzing
5CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89%Q01538(Myelin transcription factor 1) HPRD:00302(in vitro;in vivo) ViewAnalyzing
6CDC2CDC2_HUMANT14KIGEG T YGVVY 16.89%MYT1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
7CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%Wee1 Phospho.ELM 7.0  ViewAnalyzing
8CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%Wee1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
9CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%Wee1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
10CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%LYN HPRD:00302(in vitro)  ViewAnalyzing
11CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%MYT1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
12CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84%LYN HPRD:00302(in vitro;in vivo)  ViewAnalyzing
13CDC2CDC2_HUMANY15IGEGT Y GVVYK 20.84% Swiss-Prot 55.0 View   
14CDC2CDC2_HUMANY19TYGVV Y KGRHK 12.81% Phospho.ELM 7.0View   
15CDC2CDC2_HUMANY19TYGVV Y KGRHK 12.81% Swiss-Prot 55.0 View   
16CDC2CDC2_HUMANS39KIRLE S EEEGV 55.70%CK2_group Phospho.ELM 7.0 ViewAnalyzing
17CDC2CDC2_HUMANS39KIRLE S EEEGV 55.70%CK2a1-rs HPRD:00302(in vitro;in vivo)  ViewAnalyzing
18CDC2CDC2_HUMANS39KIRLE S EEEGV 55.70%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
19CDC2CDC2_HUMANS39KIRLE S EEEGV 55.70%CK2a1 HPRD:00302(in vitro;in vivo)  ViewAnalyzing
20CDC2CDC2_HUMANT161PIRVY T HEVVT 14.54% Swiss-Prot 55.0 View   
21CDC2CDC2_HUMANT161PIRVY T HEVVT 14.54%CDK7 Phospho.ELM 7.0  ViewAnalyzing
22CDC2CDC2_HUMANT161PIRVY T HEVVT 14.54%CDK7 HPRD:00302(in vitro;in vivo)  ViewAnalyzing